Pfizer Innovent Oncology Deal | Lucid Diligence Brief
Pfizer Innovent Oncology Deal tests China-originated ADC and multi-specific…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
Lucid Diligence Brief: Olema OP-3136 and Bayer Darolutamide Deal
Lucid Diligence Brief: Olema expands OP-3136 into metastatic…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Insilico and Human Longevity collaboration
Lucid Diligence Brief: Insilico Medicine and Human Longevity collaborate on AI…
Lucid Diligence Brief: NeuroXT and BIDMC Expand Alzheimer’s AI Imaging Collaboration
Lucid Diligence Brief: NeuroXT and BIDMC expand their Alzheimer’s AI imaging…
Lucid Diligence Brief: Polyphonic Intelligent OR Network Launched by J&J for AI-Powered Surgery
Lucid Diligence Brief: Polyphonic Intelligent OR Network by J&J uses AI to…
Lucid Diligence Brief: BMS Deploys Anthropic Claude Enterprise
Lucid Diligence Brief: BMS Deploys Anthropic Claude Enterprise Across R&D,…
Lucid Diligence Brief: Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Lucid Diligence Brief: Incyte and Genesis Molecular AI expand collaboration…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI Partnership in CNS Oncology
Lucid Diligence Brief: Plus Therapeutics and Ephemeral AI partnership raises…